To systematically map the published literature on the Endotoxin Activity Assay (EAA) in human patients with sepsis, summarizing clinical contexts, findings, and identifying trends and knowledge gaps, emphasizing the importance of these aspects.
Key Findings:
Sepsis affects 50 million people annually, with high mortality rates.
EAA offers advantages over traditional LAL assay, including rapid results and high specificity.
EAA levels may correlate with endotoxemia and systemic inflammatory response syndrome (SIRS), but clear cut-off values are not established.
EAA results do not always correlate with LAL results, and elevated levels can occur in non-bacterial infections.
Clinical interpretation of EAA values remains controversial, with proposed cut-off values lacking consensus and requiring further validation.
Interpretation:
EAA may help identify patients with severe sepsis who could benefit from endotoxin removal therapies, but its clinical application and interpretation require further validation in clinical settings.
Limitations:
Lack of established cut-off values for EAA results.
Limited understanding of the proportional distribution of sepsis patients across EAA categories.
Existing therapies may be ineffective for extremely high EAA results.
Potential biases in the literature reviewed.
Conclusion:
The scoping review highlights the potential of EAA in sepsis management but underscores the urgent need for further research to clarify its clinical utility and interpretation.
